Scholars Central

Research articlePublished 13 Mar 2018

Long-term management of dry eye by once-daily use of Chitosan-N-Acetylcysteine (Lacrimera®) eye drops.

Authors: Katrin Lorenz, Gerhard Garhofer, Sonja Hoeller, Ward Peterson, Raimund M Vielnascher, Zrinka Ivezi? Schoenfeld, Martin Prinz

Journal of Clinical Ophthalmology

Volume 2 · Issue 1 · Pages 47–54

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Purpose: To evaluate the tolerability, safety and performance of chitosan-N-acetylcysteine (CNAC) eye drops in patients with mild-to-moderate dry eye disease after long-term once-daily use. Methods: This prospective, non-comparative, multicenter trial comprised a 2-week run-in phase (concomitant use of hyaluronic acid eye drops allowed), a 4-week main phase, and a voluntary 20 week long-term safety follow-up (LTSFU). Assessments (improvement in dry eye symptoms, Ocular Surface Disease Index (OSDI), matrix metallopeptidase 9 (MMP-9) status, tear film break-up time (TBUT), corneal staining) were made bi-weekly up to Week 6 and every four weeks thereafter. Results: Out of 102 patients included, 80 entered and 77 (96%) completed the main phase, 48 joined the LTSFU and 31 (65%) completed 26 weeks of treatment. Compared to baseline, both the dry eye symptoms intensity score and the Ocular Surface Disease Index were reduced by 55% and 47%, respectively at week 6 and by 67% (right eye) and 78% (left eye) and 70% at Week 26, respectively (p<0.0001). The tear film break-up time increased by ∼15% (p<0.05) at Week 6. Matrix metallopeptidase-9 shifted to negative in 59% of eyes and conjunctival or eyelid abnormalities disappeared in ∼30%. Most common AEs were eye irritation, blurred vision, foreign body sensation and corneal staining. Global treatment satisfaction was ∼80% at Weeks 6 and 26, compared to 65% for previous treatment before entering the study. Conclusion: Once-daily use of C-NAC eye drops is a highly effective and convenient treatment option for dry eye disease. C-NAC can be safely used long term.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Clinical Ophthalmology.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Clinical Ophthalmology
  • SubjectOphthalmology & Optometry
  • BylineArticles whose byline prints “Katrin Lorenz”
  • BylineArticles whose byline prints “Gerhard Garhofer”
  • BylineArticles whose byline prints “Sonja Hoeller”
  • BylineArticles whose byline prints “Ward Peterson”
  • BylineArticles whose byline prints “Raimund M Vielnascher”
  • BylineArticles whose byline prints “Zrinka Ivezi? Schoenfeld”
  • BylineArticles whose byline prints “Martin Prinz”